I did a brief email Q&A interview with Dr. Bob Lanza of Advanced Cell Technology (ACT) on their new hES MSCs pre-clinical data for Multiple Sclerosis. I discussed the paper itself in a concise review yesterday here. Thanks to Dr. Lanza for doing the interview. 1. Were you surprised at the fact that the therapeutic […]
Interview with Bob Lanza on new ACT MSCs for MS paper Read More »
There is more good news from leading stem cell biotech Advanced Cell Technology (ACT) on preclinical rodent studies using stem cells to treat mice with an MS-like condition. They published a new paper in the journal Stem Cell Reports entitled “Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of
Advanced Cell Technology (ACT) Revs Up Pre-Clinical Studies for MS Read More »
Late last year I was hearing some exciting things about California Stem Cell, Inc. under the leadership of Hans Keirstead. (2020 update: interestingly 3 years ago Keirstead ran for congress, but the campaign didn’t quite make it.) In fact, I thought a big move for California Stem was in the cards for 2014 and looking into
As Predicted, Big News For California Stem Cell, Inc.: Purchased by NeoStem Read More »
Stem cell biotech, Advanced Cell Technology (ACT; stock symbol ACTC), has started off 2014 with indications that it is in a phase of rapid evolution. Some changes, such as today’s announced departure of now former CEO Gary Rabin (see my 2013 interview with him here), are already in the public domain, but other big developments
Big Changes Unfolding at Advanced Cell Technology (ACTC) Read More »
I’ve added a fun and helpful new feature on the right side bar of the blog in the form of a stem cell biotech stock ticker. The ticker is for some of the most widely held stem and cellular medicine companies. A sample screen shot is shown in this post. Quite a few stem cell-related
New Stem Cell Stock Ticker Read More »
The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal,
Mesoblast (MSB) buys Osiris (OSIR) stem cell unit Read More »
BioTime (BTX), via its subsidiary Asterias, has formally purchased the Geron (GERN) embryonic stem cell (ESC) research program and assets. Incidentally, Asterias in nature refers to a genus of sea stars including starfish and you can see it in their logo. Perhaps this was chosen given the amazing regenerative capacity of starfish? You may recall
Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program Read More »
This is the first in a series of guest posts on what folks believe are the best compliant stem cell companies out there. You can submit a potential guest post on this topic to me until August 30. Editor’s notes: Pete submitted this to me on Sunday, well before today’s big Osiris news. He must
Pete Shuster on His Choice of Best Stem Cell Company: Osiris Read More »
Stem cell & cellular medicine biotech, Osiris, reported a major success today with its cell-based treatment of Diabetic foot ulcers. The data are about as good as it gets. The company’s Grafix product for the ulcers was three times more effective than the control. A cross-over phase where those given the control were switched to
Osiris success with Diabetic foot ulcers is a giant step Read More »
When you want to both know the real history of the pluripotent stem cell-based biotech industry and perspectives on its future, there are only a handful of people to turn to and one of them is definitely Dr. Michael West, CEO of BioTime. I’m doing a several part series of blog posts on a lengthy
BioTime CEO Mike West Interview Part 2: Geron & hESC Read More »